🌏Respirology
Impact & timing of pulm rehab in patients undergoing bronchoscopic lung volume reduction with endobronchial valves: A multicentre randomized controlled trial in patients with severe #emphysema reported in #Respirology#OpenAccess
https://t.co/VioeDsNSZo
@hartjo82
ERJOR: Heterogeneity index, the difference in emphysematous destruction between the targeted and ipsilateral lobe, cannot distinguish responders from nonresponders for endobronchial valve treatment, but does affect the degree of clinical improvement https://t.co/I2J2D9skD4
ERJOR: A substantial number of patients still experience benefit 3 years after lung volume reduction treatment with endobronchial valves. This benefit includes quality of life, which is an important outcome for patients with end-stage COPD. https://t.co/ViBuN5ia9i
Although accelerometers are extensively validated to estimate energy expenditure in patients with COPD, they show significant differences in non-worn time and type of activity registration https://t.co/7HQJIZEZXW
Dirk- Jan Slebos, longarts in het #UMCG, stapt zaterdag in Parijs op de pedalen voor een bijzondere gebeurtenis. Hij helpt de Franse Philippe Poncet, voormalig ski-crack, het werelduurrecord baanfietsen voor COPD-patiënten te vestigen https://t.co/EnEQAxtsil
EBV treatment for severe emphysema patients improves clinical and patient reported outcomes and has become a guideline treatment, but also has future challenges. https://t.co/ZCWAjCUoji